5月23日,金斯瑞生物科技股价上涨4.59%,报12.30港元。其联营公司传奇生物宣布将在2025年ASCO与EHA大会上发布CARVYKTI®(西达基奥仑赛)治疗多发性骨髓瘤的最新临床资料。此消息推动金斯瑞股价三连阳,成交额达1.53亿港元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.